Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Arthritis, Rheumatoid | 29 | 2021 | 2043 | 6.19 | Why? |
| Antirheumatic Agents | 32 | 2021 | 3023 | 5.10 | Why? |
| Tumor Necrosis Factor-alpha | 9 | 2020 | 2483 | 2.07 | Why? |
| Connective Tissue Diseases | 3 | 2021 | 187 | 1.56 | Why? |
| Arthritis, Psoriatic | 6 | 2020 | 625 | 1.45 | Why? |
| Delphi Technique | 3 | 2018 | 1257 | 1.13 | Why? |
| Arthritis | 4 | 2020 | 288 | 1.07 | Why? |
| Adalimumab | 2 | 2017 | 389 | 1.02 | Why? |
| Biological Therapy | 2 | 2017 | 456 | 0.96 | Why? |
| Metacarpophalangeal Joint | 1 | 2021 | 13 | 0.93 | Why? |
| Scleroderma, Systemic | 5 | 2020 | 583 | 0.86 | Why? |
| Arthritis, Reactive | 1 | 2021 | 64 | 0.82 | Why? |
| Rheumatic Diseases | 9 | 2021 | 2675 | 0.79 | Why? |
| Receptors, Interleukin-6 | 2 | 2017 | 1383 | 0.75 | Why? |
| Abatacept | 2 | 2017 | 192 | 0.73 | Why? |
| Spondylitis, Ankylosing | 2 | 2017 | 231 | 0.71 | Why? |
| Methotrexate | 5 | 2021 | 471 | 0.63 | Why? |
| Etanercept | 1 | 2017 | 162 | 0.63 | Why? |
| Microscopic Polyangiitis | 1 | 2015 | 31 | 0.60 | Why? |
| Pyrroles | 1 | 2018 | 292 | 0.59 | Why? |
| Pulmonary Alveoli | 1 | 2020 | 867 | 0.57 | Why? |
| Antibodies, Monoclonal, Humanized | 6 | 2020 | 9335 | 0.57 | Why? |
| Churg-Strauss Syndrome | 1 | 2015 | 61 | 0.57 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.54 | Why? |
| Biological Products | 2 | 2018 | 2331 | 0.50 | Why? |
| Granulomatosis with Polyangiitis | 1 | 2015 | 161 | 0.49 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2020 | 1380 | 0.47 | Why? |
| Piperidines | 1 | 2018 | 795 | 0.47 | Why? |
| Medication Adherence | 1 | 2021 | 1270 | 0.44 | Why? |
| Physical Examination | 1 | 2017 | 755 | 0.44 | Why? |
| Psoriasis | 3 | 2020 | 1739 | 0.44 | Why? |
| Rheumatology | 5 | 2021 | 1213 | 0.42 | Why? |
| Italy | 21 | 2021 | 38444 | 0.41 | Why? |
| Consensus | 5 | 2018 | 6345 | 0.41 | Why? |
| Pyrimidines | 1 | 2018 | 1557 | 0.41 | Why? |
| Immunosuppressive Agents | 4 | 2021 | 6331 | 0.41 | Why? |
| Sleep Initiation and Maintenance Disorders | 1 | 2021 | 1692 | 0.38 | Why? |
| Patient Selection | 3 | 2018 | 4560 | 0.37 | Why? |
| Polymyalgia Rheumatica | 2 | 2006 | 64 | 0.36 | Why? |
| Evidence-Based Medicine | 2 | 2018 | 3228 | 0.35 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.35 | Why? |
| Drug Therapy, Combination | 8 | 2018 | 7268 | 0.33 | Why? |
| Symptom Assessment | 2 | 2020 | 4967 | 0.33 | Why? |
| Prednisone | 2 | 2017 | 652 | 0.32 | Why? |
| Immunocompromised Host | 2 | 2020 | 5150 | 0.32 | Why? |
| Clinical Decision-Making | 2 | 2017 | 3755 | 0.31 | Why? |
| Rheumatologists | 2 | 2020 | 346 | 0.30 | Why? |
| Remission Induction | 3 | 2018 | 950 | 0.30 | Why? |
| Spondylarthritis | 2 | 2018 | 174 | 0.29 | Why? |
| Periodicals as Topic | 1 | 2018 | 1492 | 0.29 | Why? |
| Janus Kinase Inhibitors | 2 | 2020 | 682 | 0.27 | Why? |
| Purines | 2 | 2020 | 816 | 0.27 | Why? |
| Registries | 5 | 2020 | 12327 | 0.27 | Why? |
| Azetidines | 2 | 2020 | 722 | 0.27 | Why? |
| Forecasting | 1 | 2018 | 4492 | 0.26 | Why? |
| Humans | 66 | 2021 | 930598 | 0.26 | Why? |
| Pneumonia, Viral | 14 | 2020 | 243684 | 0.24 | Why? |
| Coronavirus Infections | 14 | 2020 | 253789 | 0.23 | Why? |
| Antibodies, Monoclonal | 2 | 2017 | 8041 | 0.22 | Why? |
| Sulfonamides | 2 | 2020 | 1294 | 0.22 | Why? |
| Treatment Failure | 2 | 2017 | 2106 | 0.22 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.22 | Why? |
| Severity of Illness Index | 8 | 2020 | 48226 | 0.21 | Why? |
| Arthritis, Juvenile | 2 | 2020 | 191 | 0.21 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.21 | Why? |
| Treatment Outcome | 9 | 2021 | 51732 | 0.21 | Why? |
| Hematopoietic Stem Cell Mobilization | 1 | 2001 | 73 | 0.21 | Why? |
| Autoimmune Diseases | 3 | 2018 | 1996 | 0.21 | Why? |
| Insurance, Disability | 1 | 2019 | 11 | 0.20 | Why? |
| Adult | 24 | 2021 | 244371 | 0.20 | Why? |
| Pandemics | 15 | 2021 | 389249 | 0.20 | Why? |
| Injections, Subcutaneous | 2 | 2018 | 647 | 0.20 | Why? |
| Pyrazoles | 2 | 2020 | 1791 | 0.19 | Why? |
| Spondylarthropathies | 1 | 2020 | 163 | 0.19 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.19 | Why? |
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 264 | 0.19 | Why? |
| Synovial Membrane | 1 | 2018 | 72 | 0.19 | Why? |
| Cyclophosphamide | 1 | 2001 | 387 | 0.19 | Why? |
| Bone Remodeling | 1 | 2018 | 59 | 0.19 | Why? |
| Sulfasalazine | 1 | 2018 | 87 | 0.18 | Why? |
| Synovitis | 1 | 2018 | 47 | 0.18 | Why? |
| Arthralgia | 1 | 2020 | 173 | 0.18 | Why? |
| Iloprost | 1 | 2018 | 38 | 0.18 | Why? |
| Middle Aged | 25 | 2021 | 270681 | 0.18 | Why? |
| Aged | 19 | 2021 | 215776 | 0.17 | Why? |
| Undifferentiated Connective Tissue Diseases | 1 | 2017 | 60 | 0.17 | Why? |
| Female | 30 | 2021 | 380317 | 0.17 | Why? |
| Male | 28 | 2021 | 367725 | 0.17 | Why? |
| Temporal Arteries | 1 | 2017 | 35 | 0.17 | Why? |
| Raynaud Disease | 1 | 2018 | 86 | 0.17 | Why? |
| Skin Ulcer | 1 | 2018 | 98 | 0.17 | Why? |
| Ultrasonography, Doppler, Color | 1 | 2017 | 107 | 0.16 | Why? |
| Hydroxychloroquine | 5 | 2020 | 12447 | 0.16 | Why? |
| Leukocyte L1 Antigen Complex | 1 | 2018 | 238 | 0.16 | Why? |
| Takayasu Arteritis | 1 | 2017 | 83 | 0.16 | Why? |
| Sick Leave | 1 | 2019 | 318 | 0.15 | Why? |
| Incidence | 5 | 2020 | 25622 | 0.15 | Why? |
| Thalidomide | 1 | 2018 | 247 | 0.15 | Why? |
| Pediatricians | 1 | 2020 | 401 | 0.15 | Why? |
| Fetal Growth Retardation | 1 | 2017 | 217 | 0.14 | Why? |
| Biological Factors | 1 | 2018 | 276 | 0.14 | Why? |
| Fibromyalgia | 1 | 2017 | 174 | 0.14 | Why? |
| Laryngostenosis | 1 | 2015 | 48 | 0.14 | Why? |
| Rituximab | 3 | 2021 | 1096 | 0.14 | Why? |
| Giant Cell Arteritis | 1 | 2017 | 137 | 0.14 | Why? |
| Interleukin-1beta | 1 | 2020 | 992 | 0.14 | Why? |
| Vasodilator Agents | 1 | 2018 | 344 | 0.14 | Why? |
| Expert Testimony | 1 | 2018 | 658 | 0.14 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.14 | Why? |
| Myositis | 1 | 2017 | 185 | 0.14 | Why? |
| Myalgia | 1 | 2020 | 1015 | 0.14 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.13 | Why? |
| Birth Weight | 1 | 2015 | 250 | 0.13 | Why? |
| Predictive Value of Tests | 3 | 2018 | 9537 | 0.13 | Why? |
| Patient Preference | 1 | 2021 | 750 | 0.13 | Why? |
| Anti-Inflammatory Agents | 2 | 2020 | 6153 | 0.13 | Why? |
| Mesenteric Ischemia | 1 | 2015 | 128 | 0.13 | Why? |
| Hospital Units | 1 | 2020 | 1017 | 0.12 | Why? |
| Telemedicine | 2 | 2021 | 25032 | 0.12 | Why? |
| Sex Distribution | 1 | 2020 | 2083 | 0.12 | Why? |
| Evidence-Based Practice | 1 | 2018 | 693 | 0.12 | Why? |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2015 | 235 | 0.11 | Why? |
| Betacoronavirus | 13 | 2020 | 204454 | 0.11 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.11 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.11 | Why? |
| Retrospective Studies | 10 | 2021 | 105322 | 0.11 | Why? |
| Virus Activation | 1 | 2016 | 480 | 0.11 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 1454 | 0.11 | Why? |
| Kaplan-Meier Estimate | 2 | 2017 | 4260 | 0.11 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.11 | Why? |
| Pre-Eclampsia | 1 | 2017 | 599 | 0.11 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.11 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.10 | Why? |
| Critical Pathways | 1 | 2020 | 1587 | 0.10 | Why? |
| Hepatitis B virus | 1 | 2016 | 882 | 0.09 | Why? |
| Intensive Care Units | 1 | 2015 | 29594 | 0.09 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.09 | Why? |
| Needs Assessment | 1 | 2018 | 2352 | 0.09 | Why? |
| Comorbidity | 4 | 2020 | 34796 | 0.08 | Why? |
| Pregnancy Complications | 1 | 2018 | 1388 | 0.08 | Why? |
| Chloroquine | 2 | 2020 | 3152 | 0.08 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.08 | Why? |
| Cross-Sectional Studies | 4 | 2021 | 53120 | 0.08 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.07 | Why? |
| Leucovorin | 1 | 2004 | 70 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Biomarkers | 4 | 2018 | 23361 | 0.06 | Why? |
| China | 2 | 2020 | 50654 | 0.06 | Why? |
| Occupational Health | 1 | 2019 | 3965 | 0.06 | Why? |
| Hemorrhage | 1 | 2015 | 3013 | 0.06 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.06 | Why? |
| Patient Acceptance of Health Care | 1 | 2021 | 5002 | 0.06 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.06 | Why? |
| Placebos | 1 | 2004 | 629 | 0.06 | Why? |
| Lung Diseases | 1 | 2015 | 2361 | 0.06 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.05 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.05 | Why? |
| Steroids | 1 | 2006 | 904 | 0.05 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.05 | Why? |
| Work Capacity Evaluation | 1 | 2019 | 33 | 0.05 | Why? |
| Diastole | 1 | 1999 | 168 | 0.05 | Why? |
| Biopsy | 2 | 2018 | 2811 | 0.05 | Why? |
| Th1-Th2 Balance | 1 | 2017 | 19 | 0.05 | Why? |
| Osteogenesis | 1 | 2018 | 95 | 0.04 | Why? |
| Sex Characteristics | 1 | 2006 | 1120 | 0.04 | Why? |
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 1996 | 13 | 0.04 | Why? |
| Drug Synergism | 1 | 2001 | 833 | 0.04 | Why? |
| Drug Administration Schedule | 1 | 2004 | 2324 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Time Factors | 2 | 2017 | 31397 | 0.04 | Why? |
| Injections, Intravenous | 1 | 2018 | 381 | 0.04 | Why? |
| Depression | 1 | 2021 | 14116 | 0.04 | Why? |
| Child | 3 | 2020 | 70012 | 0.04 | Why? |
| Drug Resistance | 1 | 2018 | 395 | 0.04 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.04 | Why? |
| Ribonucleoproteins | 1 | 1996 | 151 | 0.04 | Why? |
| Autoantibodies | 2 | 2017 | 2094 | 0.04 | Why? |
| Fingers | 1 | 2018 | 221 | 0.04 | Why? |
| Anxiety | 1 | 2021 | 17311 | 0.04 | Why? |
| Infant, Small for Gestational Age | 1 | 2015 | 151 | 0.04 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.03 | Why? |
| Geography | 1 | 2021 | 1801 | 0.03 | Why? |
| Educational Status | 1 | 2021 | 1451 | 0.03 | Why? |
| Maternal Age | 1 | 2015 | 244 | 0.03 | Why? |
| Infant, Low Birth Weight | 1 | 2015 | 243 | 0.03 | Why? |
| Respiratory Insufficiency | 1 | 2015 | 7301 | 0.03 | Why? |
| Heart Failure | 1 | 2015 | 6638 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Age of Onset | 1 | 2015 | 557 | 0.03 | Why? |
| Double-Blind Method | 1 | 2004 | 5988 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| Critical Illness | 1 | 2015 | 17281 | 0.03 | Why? |
| Feasibility Studies | 1 | 2021 | 3467 | 0.03 | Why? |
| Ventricular Dysfunction, Left | 1 | 1999 | 993 | 0.03 | Why? |
| Pregnancy | 3 | 2018 | 23879 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.03 | Why? |
| Patient Compliance | 1 | 2020 | 1468 | 0.03 | Why? |
| Organizational Innovation | 1 | 2020 | 2468 | 0.02 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.02 | Why? |
| Employment | 1 | 2021 | 1754 | 0.02 | Why? |
| Health Surveys | 1 | 2020 | 2841 | 0.02 | Why? |
| RNA-Binding Proteins | 1 | 1996 | 1022 | 0.02 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.02 | Why? |
| Qualitative Research | 1 | 2020 | 4337 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2020 | 3493 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2018 | 2844 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.02 | Why? |
| Blood Sedimentation | 1 | 2006 | 508 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2015 | 5440 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Ambulatory Care | 1 | 2021 | 4947 | 0.02 | Why? |
| Europe | 1 | 2019 | 12702 | 0.01 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.01 | Why? |
| Mice | 1 | 2021 | 21357 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Hemoglobins | 1 | 2006 | 958 | 0.01 | Why? |
| Animals | 2 | 2021 | 78931 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Systole | 1 | 1999 | 252 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Heterogeneous Nuclear Ribonucleoprotein A1 | 1 | 1996 | 15 | 0.01 | Why? |
| Echocardiography, Doppler | 1 | 1999 | 269 | 0.01 | Why? |
| Polypyrimidine Tract-Binding Protein | 1 | 1996 | 10 | 0.01 | Why? |
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 1996 | 28 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Prognosis | 2 | 2017 | 32490 | 0.01 | Why? |
| Case-Control Studies | 1 | 2015 | 17671 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Mitral Valve | 1 | 1999 | 342 | 0.01 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 393 | 0.01 | Why? |
| Cell Nucleus | 1 | 1996 | 399 | 0.01 | Why? |
| Infant, Newborn | 1 | 2015 | 23105 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.01 | Why? |
| Regression Analysis | 1 | 1999 | 2484 | 0.01 | Why? |
| Ventricular Function, Left | 1 | 1999 | 1555 | 0.01 | Why? |
| Blood Pressure | 1 | 1999 | 2198 | 0.01 | Why? |
| Recombinant Proteins | 1 | 1996 | 3786 | 0.00 | Why? |
| Gene Expression | 1 | 1996 | 3332 | 0.00 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 7868 | 0.00 | Why? |